DTC Corrective Advertising Study From FDA Will Have Longer Horizon
This article was originally published in The Pink Sheet Daily
In response to public comments, FDA has extended the length of time between which study participants will view a direct-to-consumer television ad for a prescription drug and be exposed to a corrective ad.
You may also be interested in...
The agency's "Bad Ad" program issued a warning letter that claims the promotion for CooperSurgical's copper-containing intrauterine contraceptive lacked any safety information.
During oral argument in the Arthrex case, several justices seemed to agree with the Federal Circuit that PTAB judges should have been appointed by the president. They could opt to get around the problem by enabling the PTO director to review all panel decisions.
US FDA’s Peter Marks notes timeframe for sponsors to seek licensure at press call announcing emergency use authorization of J&J’s vaccine; Acting Commissioner Woodcock says effectiveness comparisons cannot be made between the three authorized vaccines since they have not been tested head-to-head.